<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bronchopulmonary dysplasia (BPD): Prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bronchopulmonary dysplasia (BPD): Prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bronchopulmonary dysplasia (BPD): Prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann R Stark, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric C Eichenwald, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Martin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory Redding, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bronchopulmonary dysplasia (BPD; also known as neonatal chronic lung disease [CLD]) is a major cause of respiratory illness in preterm infants. It is an important contributing factor in the increased risk of mortality and morbidity in the preterm population.</p><p>This topic will provide an overview of strategies used to prevent BPD. Other related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5023.html" rel="external">"Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4977.html" rel="external">"Bronchopulmonary dysplasia (BPD): Management and outcome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6379.html" rel="external">"Complications and long-term pulmonary outcomes of bronchopulmonary dysplasia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/115896.html" rel="external">"Pulmonary hypertension associated with bronchopulmonary dysplasia"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prematurity</strong> – Different degrees of prematurity are defined by gestational age (GA), which is calculated from the first day of the mother's last period, or birth weight (BW), as summarized in the table  (<a class="graphic graphic_table graphicRef119362" href="/d/graphic/119362.html" rel="external">table 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4966.html" rel="external">"Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality", section on 'Definitions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BPD </strong>– BPD is a chronic lung disease characterized disruption of pulmonary development and/or lung injury in the context of preterm birth. Clinically, BPD is defined as an ongoing need for supplemental oxygen and/or respiratory support at either 28 days postnatal age or 36 weeks postmenstrual age (PMA) in a preterm neonate with radiographic evidence of parenchymal lung disease  (<a class="graphic graphic_diagnosticimage graphicRef93656" href="/d/graphic/93656.html" rel="external">image 1</a>). Various criteria are used to define BPD, as summarized in the  (<a class="graphic graphic_table graphicRef119071" href="/d/graphic/119071.html" rel="external">table 2</a>) and discussed in detail separately. (see  <a class="medical medical_review" href="/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Definitions and severity of BPD'</a>). </p><p></p><p class="headingAnchor" id="H2224013774"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>The following is a summary of the strategies that we use to reduce the incidence of BPD in infants who are at risk for developing BPD. The combination of interventions addresses the multiple risk factors implicated in the pathogenesis of BPD  (<a class="graphic graphic_algorithm graphicRef121133" href="/d/graphic/121133.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H3263623169"><span class="h2">Initial general measures</span><span class="headingEndMark"> — </span>General measures are provided to all infants who are at risk for BPD (extremely preterm [EPT] infant, gestational age &lt;28 weeks).</p><p class="bulletIndent1"><span class="glyph">●</span>Antenatal steroids – Antenatal glucocorticoids are appropriate for pregnant woman at 23 to 34 weeks of gestation at high risk for preterm delivery within the next seven days. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fluid management – After the first week of life, fluid intake is generally restricted to 130 to 140 mL/kg per day to maintain neutral or slightly negative fluid balance. Fluid status and nutritional status is monitored frequently, and fluid intake modified to avoid dehydration and overhydration and to ensure adequate growth. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Fluid management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutrition – In our centers, nutritional goals are set to provide adequate caloric intake to promote somatic and lung growth [<a href="#rid1">1</a>]. Mother's breast milk is the preferred nutritional source, and if not available, we use donor breast milk. (See  <a class="medical medical_review" href="/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13360" href="/d/drug information/13360.html" rel="external">Caffeine</a> – We administer caffeine to all EPT infants within the first 24 hours of life. These neonates have the highest risk for BPD. (See  <a class="medical medical_review" href="/d/html/5048.html" rel="external">"Management of apnea of prematurity", section on 'Caffeine'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">Vitamin A</a> – One of the authors of this topic routinely uses vitamin A (if available) in ventilator-dependent extremely low birth weight (ELBW) infants (birth weight &lt;1000 g). (See <a class="local">'Vitamin A'</a> below.)</p><p></p><p class="headingAnchor" id="H4041142495"><span class="h2">Respiratory support</span><span class="headingEndMark"> — </span>The goal for respiratory support for infants at risk for BPD is to maintain adequate oxygenation and ventilation while minimizing respiratory intervention that may lead to lung injury. Our approach is briefly summarized here. These interventions are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management"</a> and  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In infants who require supplemental oxygen, we set a peripheral oxygen saturation (SpO<sub>2</sub>) target range of 90 to 95 percent. (See <a class="local">'Ventilation strategies to minimize lung injury'</a> below and  <a class="medical medical_review" href="/d/html/112392.html" rel="external">"Neonatal target oxygen levels for preterm infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In most preterm infants, we use early positive airway pressure support (typically with continuous positive airway pressure [CPAP]). (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Early positive pressure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In preterm infants who require intubation soon after birth, we provide early surfactant therapy. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Surfactant therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In preterm infants with respiratory failure, we use a mechanical ventilation strategy that aims to minimize ventilator-induced lung injury (VILI). The approach is summarized in the table  (<a class="graphic graphic_table graphicRef131155" href="/d/graphic/131155.html" rel="external">table 3</a>) and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates", section on 'Clinical approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In infants with severe persistent respiratory failure despite optimal settings on conventional ventilation, a trial of high-frequency ventilation (HFV) is used to minimize VILI. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates", section on 'Transition to HFV'</a>.)</p><p></p><p>The role that mechanical ventilation and oxygen toxicity play in the pathogenesis of BPD is discussed separately. (See  <a class="medical medical_review" href="/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H2081175246"><span class="h2">Postnatal glucocorticoids</span><span class="headingEndMark"> — </span>We do <strong>not</strong> routinely administer postnatal systemic or inhaled glucocorticoids to prevent BPD. Systemic glucocorticoids are reserved for EPT infants who remain ventilator-dependent and/or require oxygen supplementation &gt;50 percent at two to four weeks postnatal age. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5023.html" rel="external">"Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">INTERVENTIONS</span></p><p class="headingAnchor" id="H902798081"><span class="h2">Overview</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measures that are routinely used</strong> – The following interventions are generally used in combination to improve outcomes (including a reduction in the risk of BPD) in at-risk preterm infants, especially extremely preterm infants (EPT; gestational age [GA] &lt;28 weeks)  (<a class="graphic graphic_algorithm graphicRef121133" href="/d/graphic/121133.html" rel="external">algorithm 1</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antenatal glucocorticoid therapy (see  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Protective ventilatory strategies that minimize barotrauma or volutrauma in infants who require respiratory support for neonatal respiratory distress (RDS)  (<a class="graphic graphic_table graphicRef131155" href="/d/graphic/131155.html" rel="external">table 3</a>) (see  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Early positive pressure'</a> and  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates"</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mother's breast milk (see  <a class="medical medical_review" href="/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a> and  <a class="medical medical_review" href="/d/html/5013.html" rel="external">"Infant benefits of breastfeeding"</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13360" href="/d/drug information/13360.html" rel="external">Caffeine</a> (see  <a class="medical medical_review" href="/d/html/5048.html" rel="external">"Management of apnea of prematurity", section on 'Caffeine'</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Modest fluid restriction (see  <a class="medical medical_review" href="/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a> and  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Fluid management'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measures that are used selectively</strong> – Preterm infants who remain ventilator-dependent at one week after birth are at high risk for developing BPD. Such neonates may benefit from additional preventive measures, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Selective us of postnatal glucocorticoid therapy in high-risk EPT infants (see  <a class="medical medical_review" href="/d/html/5023.html" rel="external">"Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants"</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some centers use <a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">vitamin A</a> supplementation (if available) in EPT infants who require mechanical ventilation support (see <a class="local">'Vitamin A'</a> below).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Selective use of a trial of diuretic therapy (see  <a class="medical medical_review" href="/d/html/4977.html" rel="external">"Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Diuretics'</a> and  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Fluid management'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measures that are not used</strong> – These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Routine use of postnatal glucocorticoid therapy in all at-risk preterm infants. This is because of concerns of adverse effects, particularly adverse neurodevelopmental outcome, with early glucocorticoid therapy, as discussed separately. (See  <a class="medical medical_review" href="/d/html/5023.html" rel="external">"Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Routine use of <a class="drug drug_pediatric" data-topicid="106992" href="/d/drug information/106992.html" rel="external">inhaled nitric oxide</a> (iNO), since this does not appear to be effective. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Inhaled nitric oxide'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Late surfactant administration, since this does not appear to be effective. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Timing'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Glucocorticoids</span></p><p class="headingAnchor" id="H5"><span class="h3">Antenatal glucocorticoids</span><span class="headingEndMark"> — </span>Antenatal glucocorticoid therapy is an effective intervention for prevention of respiratory distress syndrome (RDS) resulting in less need for mechanical ventilation and oxygen supplementation (risk factors for BPD). Antenatal glucocorticoids are appropriate for pregnant individuals from 23 to 34 weeks of gestation who are at risk for preterm delivery within the next seven days. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Postnatal glucocorticoids</span><span class="headingEndMark"> — </span>We do <strong>not</strong> routinely administer postnatal systemic or inhaled glucocorticoids to prevent BPD. Systemic glucocorticoids are reserved for EPT infants who remain ventilator-dependent and/or require oxygen supplementation &gt;50 percent at a postnatal age of two to four weeks. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5023.html" rel="external">"Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Surfactant</span><span class="headingEndMark"> — </span>Exogenous surfactant therapy given within the first 30 to 60 minutes after birth is effective in the prevention and treatment of RDS and reduces the need for mechanical ventilation and oxygen supplementation (risk factors for BPD). The use of early surfactant to prevent and treat RDS is discussed separately. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Surfactant therapy'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Fluid management</span><span class="headingEndMark"> — </span>The goal of fluid management is to maintain neutral or slightly negative fluid balance. Our usual practice is to restrict total fluid intake to 130 to 140 mL/kg per day after the first week of life. However, the fluid status of the patient must be monitored frequently to avoid dehydration or overhydration as fluid needs widely vary in preterm infants due to differences in insensible fluid loss. Caloric intake and growth should be closely monitored. (See  <a class="medical medical_review" href="/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a>.)</p><p>The available evidence does not support the routine use of diuretic therapy in maintaining a neutral or negative fluid balance to prevent BPD. However, it may be reasonable to selectively use diuretic therapy as a trial in chronically ventilator-dependent infants with moderate to severe pulmonary impairment despite adequate fluid restriction. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Fluid management'</a>.)</p><p>Use of diuretics in the management of infants with established BPD is discussed separately. (See  <a class="medical medical_review" href="/d/html/4977.html" rel="external">"Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Diuretics'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Ventilation strategies to minimize lung injury</span><span class="headingEndMark"> — </span>Mechanical ventilation (MV) has been a lifesaving intervention in the care of preterm infants at risk for RDS due to premature lung development. However, mechanical ventilation causes tissue injury and inflammation due to volutrauma that contributes to BPD. As a result, MV strategies aim to minimize lung injury while achieving adequate oxygenation and ventilation. These strategies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of MV through preferential use of noninvasive respiratory support (eg, nasal continuous positive airway pressure [nCPAP]) when possible. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Early positive pressure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of volume-targeted ventilation (VTV) using low tidal volumes (4 to 6 mL/kg). (See  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates", section on 'Clinical approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of high-frequency oscillatory or jet ventilation (HFOV or HFJV) as a rescue therapy. (See  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates", section on 'Transition to HFV'</a>.)</p><p></p><p>The approach is summarized in the table  (<a class="graphic graphic_table graphicRef131155" href="/d/graphic/131155.html" rel="external">table 3</a>), and discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Caffeine</span><span class="headingEndMark"> — </span>For most ELBW infants (BW &lt;1000 g), we suggest prophylactic <a class="drug drug_pediatric" data-topicid="13360" href="/d/drug information/13360.html" rel="external">caffeine</a> starting on the first day of life. The available clinical trial data suggest this intervention is safe and effective for reducing BPD and perhaps other long-term complications. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/5048.html" rel="external">"Management of apnea of prematurity", section on 'Caffeine'</a>.)</p><p class="headingAnchor" id="H900726961"><span class="h2">Vitamin A</span><span class="headingEndMark"> — </span>EPT infants may have <a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">vitamin A</a> deficiency, which may promote the development of BPD [<a href="#rid2">2</a>]. However, data are conflicting as to whether vitamin A supplementation reduces the incidence of BPD. If there is a benefit, it appears to be modest. </p><p>Since the incidence of BPD varies among neonatal intensive care units (NICUs), the decision to use <a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">vitamin A</a> supplementation may depend upon the local incidence of BPD and the availability and cost of the drug [<a href="#rid3">3</a>]. For example, one of the authors of this topic routinely uses vitamin A supplementation at their center as a preventive measure in EPT infants who require mechanical ventilation (if the drug is available); whereas the other author does not routinely use it at their center. At most centers where vitamin A is used, its use is limited to EPT infants who require mechanical ventilation. </p><p>When <a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">vitamin A</a> is given, it is administered within 24 hours after birth as an intramuscular (IM) injection of 5000 international units. This dose is then provided three times per week for four weeks. </p><p>Enteral water-soluble <a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">vitamin A</a> is <strong>not</strong> used for this purpose because, although it may increases plasma retinol levels in EPT infants, it does not appear to reduce the severity of BPD [<a href="#rid4">4,5</a>].</p><p>Evidence supporting IM <a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">vitamin A</a> supplementation includes the following: </p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of five trials (884 neonates), IM <a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">vitamin A</a> supplementation compared with control modestly reduced rates of BPD; however, the finding did not achieve statistical significance (68 versus 74 percent; relative risk [RR] 0.93, 95% CI 0.86-1.01) [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent multicenter retrospective study from the Pediatrix Medical Group of neonates from 2010 to 2012 reported that the shortage of <a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">vitamin A</a> in the United States that began in 2010 did not affect the incidence of mortality or BPD in the participating NICUs [<a href="#rid7">7</a>]. During the study period, vitamin A supplementation in patients decreased from a level of 27 percent to 2 percent as the supply of vitamin decreased. A multivariable analysis demonstrated that vitamin A supplementation was not an independent risk factor for death or BPD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">Vitamin A</a> may be beneficial in a subset of preterm infants, as suggested by a post-hoc subgroup analysis of data from the largest placebo-controlled trial [<a href="#rid8">8</a>]. In this report, the benefit of vitamin A therapy was greater for infants at a lower risk for BPD than those at a higher risk. However, as noted by the authors, data used for this study was from 1996 to 1997 and other aspects of clinical care have changed, which may have impacted these results.</p><p></p><p class="headingAnchor" id="H728031094"><span class="h2">Breast milk</span><span class="headingEndMark"> — </span>Mother's own milk is the preferred form of nutrition for preterm infants as it offers several advantages over formula, including prevention of BPD. (See  <a class="medical medical_review" href="/d/html/5050.html" rel="external">"Human milk feeding and fortification of human milk for premature infants", section on 'Benefits of mother's milk'</a>.)</p><p>A meta-analysis of 17 cohort studies and 5 RCTs (8661 neonates) demonstrated that human milk compared with formula is associated with a lower incidence of BPD, although the certainty of this finding is low [<a href="#rid9">9</a>]. In addition, an observational study found breast milk from the mother reduced the risk of BPD and reported a dose-response relationship with an increased reduction in BPD as the volume of consumed breast milk increased [<a href="#rid10">10</a>]. However, the results of this study are limited by the potential of confounding factors.</p><p class="headingAnchor" id="H1521045433"><span class="h2">Other interventions</span><span class="headingEndMark"> — </span>Interventions that are ineffective in preventing BPD include <a class="drug drug_pediatric" data-topicid="106992" href="/d/drug information/106992.html" rel="external">inhaled nitric oxide</a> alone or in combination with surfactant, supplementation with docosahexaenoic acid, and sustained inflation in the delivery room for infants requiring respiratory support.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled nitric oxide</strong><strong> (iNO)</strong> – The available data do not support the use of iNO (either alone or in combination with surfactant) as an intervention to prevent BPD. We agree with the guidance of the expert panel convened by the National Institute of Health and a 2014 American Academy of Pediatrics clinical report that recommend <strong>against</strong> the use of iNO in the routine management of preterm infants below 34 weeks gestation who require respiratory support [<a href="#rid11">11,12</a>]. </p><p></p><p class="bulletIndent1">Data on the use of iNO in the management of preterm neonates with RDS are discussed separately. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Inhaled nitric oxide'</a>.)</p><p></p><p class="bulletIndent1">However, iNO is a well-established treatment for term or late preterm infants with persistent pulmonary hypertension, as discussed separately. (See  <a class="medical medical_review" href="/d/html/135094.html" rel="external">"Persistent pulmonary hypertension of the newborn (PPHN): Management and outcome", section on 'Inhaled nitric oxide (iNO)'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late surfactant therapy</strong> – Late deficiency of postnatal surfactant production or surfactant dysfunction has been proposed as a contributor for the pathogenesis of BPD because it may be associated with episodes of respiratory deterioration in ventilator-dependent preterm infants. However, late administration of surfactant does not appear to reduce the risk of BPD, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Timing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination of steroid and surfactant</strong> – Data on the use of combination surfactant plus <a class="drug drug_pediatric" data-topicid="13096" href="/d/drug information/13096.html" rel="external">budesonide</a> are limited. This therapy cannot be recommended until there are more definitive data establishing its safety and efficacy. The data supporting this intervention are discussed separately. (See  <a class="medical medical_review" href="/d/html/5023.html" rel="external">"Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants", section on 'Intratracheal glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-chain fatty acids </strong>– Docosahexaenoic acid (DHA) and other omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) are integral components of the brain and retinal phospholipid membrane. Preterm infants miss some of the fetal accretion of DHA, which normally occurs during the third trimester of pregnancy. Based upon the available evidence, direct or indirect LCPUFA supplementation does not appear to prevent BPD. However, LCPUFA supplementation appears to have other beneficial effects in preterm infants, particularly on neurocognitive and visual development. Recommendations regarding maternal and infant LCPUFA supplementation are provided separately. (See  <a class="medical medical_review" href="/d/html/83231.html" rel="external">"Long-chain polyunsaturated fatty acids (LCPUFA) for preterm and term infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sustained inflation in the delivery room</strong> – Sustained lung inflation during neonatal resuscitation in the delivery room may be harmful and should be <strong>avoided</strong>, as discussed separately. (See  <a class="medical medical_review" href="/d/html/5015.html" rel="external">"Neonatal resuscitation in the delivery room", section on 'Sustained inflation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superoxide dismutase</strong> – Superoxide dismutase is a naturally occurring enzyme that provides defense against oxidative injury, which has been implicated in the pathogenesis of BPD. In the available clinical trials, postnatal administration of superoxide dismutase did not have any apparent benefit in terms of reducing the incidence of BPD, other morbidities, or mortality [<a href="#rid13">13</a>]. Superoxide dismutase is not available for clinical use, and it remains an investigational drug. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pentoxifylline</strong> – <a class="drug drug_pediatric" data-topicid="12694" href="/d/drug information/12694.html" rel="external">Pentoxifylline</a> is a xanthine derivative with anti-inflammatory properties. The use of nebulized pentoxifylline as a preventive measure for BPD was studied in a single small pilot randomized trial [<a href="#rid14">14,15</a>]. As such, additional data are needed before pentoxifylline can be recommended as a routine measure to prevent or treat BPD in neonates. Studies investigating the use of pentoxifylline in the treatment of neonatal sepsis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Pentoxifylline'</a>.)</p><p></p><p class="headingAnchor" id="H2563667581"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115866.html" rel="external">"Society guideline links: Bronchopulmonary dysplasia"</a>.)</p><p class="headingAnchor" id="H25799103"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83626.html" rel="external">"Patient education: Bronchopulmonary dysplasia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effective interventions</strong> – Interventions that are effective for reducing the risk of bronchopulmonary dysplasia (BPD) in extremely preterm (EPT) infants (gestational age [GA] &lt;28 weeks) who are at risk for BPD include  (<a class="graphic graphic_algorithm graphicRef121133" href="/d/graphic/121133.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antenatal glucocorticoid therapy</strong> – Antenatal glucocorticoid therapy for pregnant individuals &lt;34 weeks gestation who are at high risk for preterm delivery, which is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nutrition and fluid management</strong> – In all preterm infants, nutritional goals are set to provide adequate caloric intake to promote somatic and lung growth, and fluid intake is adjusted to maintain neutral or slightly negative water balance. Mother's breast milk is the preferred nutritional source, and if not available, donor breast milk is used. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a> and  <a class="medical medical_review" href="/d/html/5026.html" rel="external">"Parenteral nutrition in premature infants"</a> and  <a class="medical medical_review" href="/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a> and  <a class="medical medical_review" href="/d/html/5050.html" rel="external">"Human milk feeding and fortification of human milk for premature infants"</a> and  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Fluid management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oxygen targets</strong> – In preterm infants who require supplemental oxygen, target oxygen saturation (SpO<sub>2</sub>) levels are set for values between 90 and 95 percent, as discussed separately. (See  <a class="medical medical_review" href="/d/html/112392.html" rel="external">"Neonatal target oxygen levels for preterm infants", section on 'Oxygen target levels'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ventilation strategies that minimize lung injury</strong> – Use of ventilation strategies that minimize lung injury, including preferential use of noninvasive modalities. The approach to mechanical ventilation in preterm infants is summarized in the table  (<a class="graphic graphic_table graphicRef131155" href="/d/graphic/131155.html" rel="external">table 3</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Clinical approach'</a> and  <a class="medical medical_review" href="/d/html/130240.html" rel="external">"Approach to mechanical ventilation in very preterm neonates"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Caffeine</strong><strong> therapy</strong> – Early <a class="drug drug_pediatric" data-topicid="13360" href="/d/drug information/13360.html" rel="external">caffeine</a> therapy is routinely given to all EPT infants, as discussed separately. (See  <a class="medical medical_review" href="/d/html/5048.html" rel="external">"Management of apnea of prematurity", section on 'Caffeine'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamin A</strong><strong> supplementation</strong> – The use of <a class="drug drug_pediatric" data-topicid="12883" href="/d/drug information/12883.html" rel="external">vitamin A</a> supplementation is center-dependent. If vitamin A is available, practitioners may consider its administration to EPT infants who require ventilatory support; however, the relative benefit of vitamin A supplementation in this setting appears to be small. (See <a class="local">'Vitamin A'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postnatal glucocorticoids</strong> – We do <strong>not</strong> routinely administer postnatal systemic or inhaled glucocorticoids to prevent BPD. Systemic glucocorticoids are reserved for EPT infants who remain ventilator-dependent and/or require oxygen supplementation &gt;50 percent at a postnatal age of two to four weeks. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5023.html" rel="external">"Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ineffective interventions</strong> – Interventions that do not appear to be effective for prevention of BPD in EPT infants include (see <a class="local">'Other interventions'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inhaled nitric oxide (iNO) (see  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Inhaled nitric oxide'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Late surfactant therapy (see  <a class="medical medical_review" href="/d/html/4997.html" rel="external">"Respiratory distress syndrome (RDS) in preterm infants: Management", section on 'Timing'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Sustained lung inflation during neonatal resuscitation (see  <a class="medical medical_review" href="/d/html/5015.html" rel="external">"Neonatal resuscitation in the delivery room", section on 'Sustained inflation'</a>)</p><p></p><p class="headingAnchor" id="H1429928470"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge James Adams, Jr., MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Biniwale MA, Ehrenkranz RA. The role of nutrition in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 2006; 30:200.</a></li><li><a class="nounderline abstract_t">Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999; 340:1962.</a></li><li><a class="nounderline abstract_t">Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2000; :CD000501.</a></li><li><a class="nounderline abstract_t">Rakshasbhuvankar AA, Simmer K, Patole SK, et al. Enteral Vitamin A for Reducing Severity of Bronchopulmonary Dysplasia: A Randomized Trial. Pediatrics 2021; 147.</a></li><li><a class="nounderline abstract_t">Manapurath RM, Kumar M, Pathak BG, et al. Enteral Low-Dose Vitamin A Supplementation in Preterm or Low Birth Weight Infants to Prevent Morbidity and Mortality: a Systematic Review and Meta-analysis. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Darlow BA, Graham PJ, Rojas-Reyes MX. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. Cochrane Database Syst Rev 2016; :CD000501.</a></li><li><a class="nounderline abstract_t">Tolia VN, Murthy K, McKinley PS, et al. The effect of the national shortage of vitamin A on death or chronic lung disease in extremely low-birth-weight infants. JAMA Pediatr 2014; 168:1039.</a></li><li><a class="nounderline abstract_t">Rysavy MA, Li L, Tyson JE, et al. Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial. J Pediatr 2021; 236:78.</a></li><li><a class="nounderline abstract_t">Huang J, Zhang L, Tang J, et al. Human milk as a protective factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2019; 104:F128.</a></li><li><a class="nounderline abstract_t">Patel AL, Johnson TJ, Robin B, et al. Influence of own mother's milk on bronchopulmonary dysplasia and costs. Arch Dis Child Fetal Neonatal Ed 2017; 102:F256.</a></li><li><a class="nounderline abstract_t">Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 2011; 127:363.</a></li><li><a class="nounderline abstract_t">Kumar P, Committee on Fetus and Newborn, American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants. Pediatrics 2014; 133:164.</a></li><li><a class="nounderline abstract_t">Albertella M, Gentyala RR, Paraskevas T, et al. Superoxide dismutase for bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2023; 10:CD013232.</a></li><li><a class="nounderline abstract_t">Lauterbach R, Szymura-Oleksiak J, Pawlik D, et al. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. J Matern Fetal Neonatal Med 2006; 19:433.</a></li><li><a class="nounderline abstract_t">Schulzke SM, Kaempfen S, Patole SK. Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2014; :CD010018.</a></li></ol></div><div id="topicVersionRevision">Topic 4992 Version 70.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860160" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The role of nutrition in the prevention and management of bronchopulmonary dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10379020" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796372" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33386338" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Enteral Vitamin A for Reducing Severity of Bronchopulmonary Dysplasia: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35921666" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Enteral Low-Dose Vitamin A Supplementation in Preterm or Low Birth Weight Infants to Prevent Morbidity and Mortality: a Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27552058" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25222512" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The effect of the national shortage of vitamin A on death or chronic lung disease in extremely low-birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34004189" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29907614" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Human milk as a protective factor for bronchopulmonary dysplasia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27806990" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Influence of own mother's milk on bronchopulmonary dysplasia and costs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21220405" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24379225" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Use of inhaled nitric oxide in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37811631" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Superoxide dismutase for bronchopulmonary dysplasia in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923699" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25418278" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
